CDAK:NSD-Codiak BioSciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 26.81

Change

0.00 (0.00)%

Market Cap

USD 0.59B

Volume

0.06M

Average Target Price

USD 31.00 (+15.63%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD87.87B 146.68 115.30
BNTX BioNTech SE

N/A

USD57.61B -99,999.99 35.63
REGN Regeneron Pharmaceuticals, Inc

N/A

USD55.99B 14.96 11.72
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD49.97B 18.40 14.51
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.15B 58.96 42.44
BGNE BeiGene, Ltd

N/A

USD32.98B N/A N/A
SGEN Seagen Inc

N/A

USD28.42B 43.69 39.29
GMAB Genmab A/S

N/A

USD28.21B 26.59 3.61
RPRX Royalty Pharma plc

N/A

USD27.26B 22.60 16.58
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CDAK

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.00% 28% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.00% 28% F 13% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.59B 59% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.60 23% F 18% F
Price / Cash Flow Ratio -9.33 54% F 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -175.30% 10% F 5% F
Return on Invested Capital -255.93% 4% F 2% F
Return on Assets -32.46% 31% F 9% F
Debt to Equity Ratio 171.35% 7% F 11% F
Technical Ratios  
Short Ratio 8.90 28% F 13% F
Short Percent 7.96% 42% F 25% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.